Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients

NCT04679272 | Completed

• 1 other identifier: RECHMPL20_0682
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

Conditions

Covid19; Rheumatoid Arthritis

Keywords

DMARDs; Biotherapy

Outcome Measures

Primary Outcomes (1)

• Hospitalization rates for COVID-19

  Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  1 day

Secondary Outcomes (6)

• Critical care transfer rate for COVID-19 and death due to COVID-19

  1 day

• Pulmonary comorbidities, corticosteroids or DMARDs use

  1 day

• Age

  1 day

• Number of Participants with co-morbidities

  1 day

• Type of clinical presentation

  1 day

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study population description: \* * Patients with RA, included in the French RMD Covid-19 cohort, with a confirmed COVID-19 diagnosis (positive PCR or serology). * Patients included in the Montpellier COVID-19 cohort, without autoimmune disease or inflammatory rheumatism, and with a confirmed COVID-19 diagnosis (positive PCR or serology).

You may qualify if:

• \- Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls.

You may not qualify if:

• Age under 18 years old
• Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

UH Montpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

COVID-19; Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Padern Guillaume, physician

  University Hospitals of Montpellier

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2020
• First Posted: December 22, 2020
• Study Start: December 1, 2020
• Primary Completion: January 30, 2021
• Study Completion: February 1, 2021
• Last Updated: March 1, 2021

Record last verified: 2021-02

Locations

FR (1)